Table 1 Descriptive characteristics of included studies

Number of studies

6

87

Total number of patients

5352

239,433

Year published^a

2014 (2012, 2016)

2014 (2012, 2016)

Region

 Europe

2 (33.3%)

47 (54.0%)

 North America

2 (33.3%)

16 (18.4%)

 Asia

0

7 (8.0%)

 Other

0

3 (3.5%)

 Multiple

2 (33.3%)

2 (2.3%)

 Unclear

0

12 (13.8%)

TAVI Approach

 Any

5 (83.3%)

57 (65.5%)

 Transfemoral

0

10 (11.5%)

 Transapical

1 (16.7%)

13 (14.9%)

 Other

0

7 (8.0%)

 Number of patients

2771

2581

78,254

161,179

 Year enrolment began

2010 (2008, 2011) (n = 6)

2010 (2008, 2011) (n = 6)

2009 (2006–2011) (n = 79)

2007 (2005–2009) (n = 76)

 Year enrolment ended

2012 (2011, 2013) (n = 6)

2012 (2011, 2013) (n = 6)

2012 (2010–2013) (n = 75)

2012 (2010, 2013) (n = 72)

Baseline surgical risk^b

 STS

6.13 ± 2.25 (n = 5)

6.20 ± 2.32 (n = 5)

9.83 ± 5.03 (n = 34)

6.76 ± 3.68 (n = 33)

 EuroSCORE I

NA

NA

18.25 ± 8.61 (n = 8)

11.16 ± 5.26 (n = 8)

 LogEuroSCORE

16.21 ± 8.77 (n = 5)

16.30 ± 8.64 (n = 5)

22.32 ± 11.29 (n = 44)

14.19 ± 8.73 (n = 44)

 EuroSCORE II

NA

NA

8.52 ± 6.58 (n = 5)

8.09 ± 5.74 (n = 5)

 NYHA

2.75 (n = 3)

2.74 (n = 3)

3.40 (n = 12)

2.62 (n = 12)